{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:07:54Z","timestamp":1788732474864,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00432-021-03610-w","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T04:02:30Z","timestamp":1616904150000},"page":"2789-2800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience"],"prefix":"10.1007","volume":"147","author":[{"given":"Vineel","family":"Bhatlapenumarthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-6912","authenticated-orcid":false,"given":"Anannya","family":"Patwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine J.","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,28]]},"reference":[{"issue":"2","key":"3610_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA et al (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121\u2013130. https:\/\/doi.org\/10.7326\/M17-2073","journal-title":"Ann Intern Med"},{"key":"3610_CR2","doi-asserted-by":"publisher","first-page":"e000144","DOI":"10.1136\/jitc-2019-000144","volume":"8","author":"SA Abou","year":"2020","unstructured":"Abou SA, Xie W, Nassar AH et al (2020) Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer 8:e000144. https:\/\/doi.org\/10.1136\/jitc-2019-000144","journal-title":"J Immunother Cancer"},{"key":"3610_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13350","author":"E Ahern","year":"2020","unstructured":"Ahern E, Allen MJ, Schmidt A et al (2020) Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). Asia Pac J Clin Oncol. https:\/\/doi.org\/10.1111\/ajco.13350","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"3610_CR4","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1200\/JOP.18.00703","volume":"15","author":"A Balaji","year":"2019","unstructured":"Balaji A, Zhang J, Wills B et al (2019) Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes. J Oncol Pract 15(9):e825\u2013e834. https:\/\/doi.org\/10.1200\/JOP.18.00703","journal-title":"J Oncol Pract"},{"issue":"17","key":"3610_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"2","key":"3610_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"17","key":"3610_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"3","key":"3610_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA, Dorfman DM, Ma FR et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257\u20131266. https:\/\/doi.org\/10.4049\/jimmunol.170.3.1257","journal-title":"J Immunol"},{"issue":"1","key":"3610_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","volume":"76","author":"L Calabrese","year":"2017","unstructured":"Calabrese L, Velcheti V (2017) Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis 76(1):1\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209782","journal-title":"Ann Rheum Dis"},{"key":"3610_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CMAR.S136818","volume":"9","author":"S Chuzi","year":"2017","unstructured":"Chuzi S, Tavora F, Cruz M et al (2017) Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 9:207\u2013213. https:\/\/doi.org\/10.2147\/CMAR.S136818","journal-title":"Cancer Manag Res"},{"issue":"6","key":"3610_CR11","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Santini D et al (2019) Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 24(6):e327\u2013e337. https:\/\/doi.org\/10.1634\/theoncologist.2018-0618","journal-title":"Oncologist"},{"key":"3610_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","volume":"7","author":"MA Couey","year":"2019","unstructured":"Couey MA, Bell RB, Patel AA et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7:165. https:\/\/doi.org\/10.1186\/s40425-019-0645-6","journal-title":"J Immunother Cancer"},{"issue":"19","key":"3610_CR13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378(19):1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"issue":"4","key":"3610_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"19","author":"MC Garassino","year":"2018","unstructured":"Garassino MC, Cho BC, Kim JH et al (2018) Durvalumab as third-line or later treatment for advanced non-smallcell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 19(4):521\u2013536. https:\/\/doi.org\/10.1016\/S1470-2045(18)30144-X","journal-title":"Lancet Oncol"},{"key":"3610_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","volume":"140","author":"ML Giaj Levra","year":"2020","unstructured":"Giaj Levra ML, Cott\u00e9 FE, Corre R et al (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer 140:99\u2013106. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.017","journal-title":"Lung Cancer"},{"issue":"1","key":"3610_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S et al (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8. https:\/\/doi.org\/10.1186\/s40425-018-0316-z","journal-title":"J Immunother Cancer"},{"key":"3610_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.038","journal-title":"Eur J Cancer"},{"issue":"Suppl 4","key":"3610_CR18","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdx225","volume":"29","author":"JBAG Haanen","year":"2018","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2018) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv264\u2013iv266. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"issue":"6","key":"3610_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","volume":"31","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff MS, Wang Y et al (2020) Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 31(6):724\u2013744. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.285","journal-title":"Ann Oncol"},{"issue":"22","key":"3610_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"issue":"10027","key":"3610_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"8","key":"3610_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"2","key":"3610_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234\u2013240. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368","journal-title":"JAMA Oncol"},{"issue":"6","key":"3610_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","volume":"17","author":"LC Kennedy","year":"2019","unstructured":"Kennedy LC, Bhatia S, Thompson JA, Grivas P (2019) Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Canc Netw 17(6):750\u2013757. https:\/\/doi.org\/10.6004\/jnccn.2019.7310 (PMID: 31200356)","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"3610_CR25","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T et al (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28(10):2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"issue":"19","key":"3610_CR26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36(19):1905\u20131912. https:\/\/doi.org\/10.1200\/JCO.2017.77.0305","journal-title":"J Clin Oncol"},{"issue":"2","key":"3610_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368\u2013376. https:\/\/doi.org\/10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"},{"issue":"19","key":"3610_CR28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"14","key":"3610_CR29","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"5","key":"3610_CR30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jgs.15750","volume":"67","author":"E Muchnik","year":"2019","unstructured":"Muchnik E, Loh KP, Strawderman M et al (2019) Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer. J Am Geriatr Soc 67(5):905\u2013912. https:\/\/doi.org\/10.1111\/jgs.15750","journal-title":"J Am Geriatr Soc"},{"issue":"64","key":"3610_CR31","doi-asserted-by":"publisher","first-page":"32298","DOI":"10.18632\/oncotarget.25949","volume":"9","author":"M Niki","year":"2018","unstructured":"Niki M, Nakaya A, Kurata T et al (2018) Immune checkpoint inhibitor re-challenge in patients with advanced nonsmall cell lung cancer. Oncotarget 9(64):32298\u201332304. https:\/\/doi.org\/10.18632\/oncotarget.25949","journal-title":"Oncotarget"},{"issue":"1","key":"3610_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H et al (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29(1):250\u2013255. https:\/\/doi.org\/10.1093\/annonc\/mdx642","journal-title":"Ann Oncol"},{"issue":"1","key":"3610_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"Suppl 13","key":"3610_CR34","doi-asserted-by":"publisher","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","volume":"10","author":"J Remon","year":"2018","unstructured":"Remon J, Mezquita L, Corral J et al (2018) Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis 10(Suppl 13):S1516\u2013S1533. https:\/\/doi.org\/10.21037\/jtd.2017.12.52","journal-title":"J Thorac Dis"},{"issue":"10066","key":"3610_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"issue":"4","key":"3610_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"9","key":"3610_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini FC, Rizvi H, Plodkowski AJ et al (2018) Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6(9):1093\u20131099. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0755","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"3610_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","volume":"10","author":"J Sattar","year":"2019","unstructured":"Sattar J, Kartolo A, Hopman WM, Lakoff JM, Baetz T (2019) The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. J Geriatr Oncol 10(3):411\u2013414. https:\/\/doi.org\/10.1016\/j.jgo.2018.07.015","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"3610_CR39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5(9):1310\u20131317. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"issue":"6","key":"3610_CR40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/cbr.2010.0865","volume":"25","author":"A Tarhini","year":"2010","unstructured":"Tarhini A, Lo E, Minor DR (2010) Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 25(6):601\u2013613. https:\/\/doi.org\/10.1089\/cbr.2010.0865","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"3610_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2019) Management of Immunotherapy-related toxicities version 1.2019. J Natl Compr Cancer Netw 17(3):255\u2013289. https:\/\/doi.org\/10.6004\/jnccn.2019.0013","journal-title":"J Natl Compr Cancer Netw"},{"key":"3610_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40425-016-0157-6","volume":"4","author":"M Uemura","year":"2016","unstructured":"Uemura M, Fa\u2019ak F, Haymaker C et al (2016) A case report of Grover\u2019s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer 4:55. https:\/\/doi.org\/10.1186\/s40425-016-0157-6","journal-title":"J Immunother Cancer"},{"key":"3610_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw E, Chodon T, Attar N et al (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35. https:\/\/doi.org\/10.1186\/1479-5876-7-35","journal-title":"J Transl Med"},{"issue":"14","key":"3610_CR44","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall Survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03610-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T10:10:02Z","timestamp":1627207802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03610-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,28]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3610"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03610-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,28]]},"assertion":[{"value":"12 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}